Doseology Investor https://validator.w3.org/feed/docs/rss2.html Doseology Uplists to OTCQB as DOSEF, Expanding U.S. Investor Access to the Emerging Oral Stimulant Pouch Category Doseology Begins Pilot Production of Caffeine-Based Energy Pouches as Feed That Brain® Enters Oral Stimulant Format Contact Home Doseology Launches Feed That Brain Oral Stimulant Pouches in the U.S. Through Direct-to-Consumer Pilot Doseology Files Annual Information Form (AIF), Strengthening Public Disclosure Record AIF Filing Enhances Transparency and Provides Consolidated Disclosure for Investors Doseology Targets Digital Nomads Investors Doseology Appoints Larry Latowsky as Executive Chairman of the Board of Directors Doseology Engages McKinney Regulatory Science Advisors to Advance Innovative Oral Pouch Product Development through Science and Regulatory Expertise Doseology Acquires Feed That Brain™ and Appoints Joseph Mimran as Strategic Advisor Doseology Appoints Patrick W. Sills as Strategic Go-to-Market Advisor Doseology Completes Extensive North American Diligence, Securing Strategic Manufacturing Agreement via U.S. Subsidiary Doseology USA Inc. Doseology Announces Launch of Corporate Communications Program About – BACK Privacy Policy About Doseology Products Now Available on Retail Shelves Doseology Announces $2M Financing to Accelerate Commercialization of Oral Stimulant Pouch Platform Doseology Launches in 31 Healthy Planet Locations Across Ontario Doseology Expands into National Retailer Sobeys Doseology Goes National with Whole Foods Market Doseology Raises $4,451,568 and Files Preliminary Non-offering Prospectus. Doseology Receives Receipt for Final Prospectus and Announces Listing on the CSE Doseology Set to Trade CSE: MOOD Doseology Prepares to Expand Mushroom Production by Hiring Dr. Wellman-Labadie to Oversee Planned Research and Development Laboratory Doseology Launches Medicinal Mushroom Product Line in Canada to Supply Increasing Demand Doseology Names CFO and Appoints New Board Member Doseology To Attend CHFA NOW Show, Sept 17-18 Doseology Appoints Maryam Marissen as CEO to Prepare for Next Growth Stage Doseology Announces Management Change Doseology Initiates Canadian Retail Sales Strategy Coast to Coast Signing with Connect Brand Management Doseology Announces Frankfurt Stock Exchange Quotation Doseology Accelerates Rollout of Medicinal Mushroom Products with National Distribution Doseology Opens to American Investors Doseology Uplists to OTCQB Market in USA Doseology Provides Corporate Update Doseology Receives Receipt for Final Prospectus and Amounts Listing on the CSE : MOOD Doseology Announces CEO Transition Doseology Grows Canadian Retail Sales with Loblaw Companies Executive Realignment at Doseology to Drive Future Expansion Doseology Invests into the Multi-Billion-Dollar U.S. Modern Oral Stimulant Market Doseology Appoints Chris Jackson, Founder of Qtrade, as Chief Executive Officer and a Director Doseology Prepares for Growth Phase in Psychedelic-Focused Mental Health Market, Completes Dealer’s License Application Doseology Announces $1.2M Private Placement to Advance Commercialization Doseology Announces Amended Private Placement Unit Price Investor Year End Update Doseology Announces Option Grant Doseology Closes $750,000 Non-Brokered Private Placement Doseology Completes Development and Test Marketing of Adaptogenic Mushroom Product Line